⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 7, 2026Journal of Medical EconomicsOpen Access

Clinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspective

Braydon Nault David Garcia Heather Cameron Andrew Revel Kevin Steele Kyle Flannery Pedro Barata

View Full Paper

Ask AI

Bookmark

Share

Key Points

This analysis aims to compare the clinical and economic outcomes of cabazitaxel and Lu-PSMA in patients with mCRPC.
Developed a cost-consequence model from the US Medicare perspective.
Evaluated costs associated with PSMA testing, drug acquisition, and supportive care among mCRPC patients.
Analyzed outcomes like overall survival, progression-free survival, and radiographic progression-free survival over an 18-month time horizon.
At 18 months, cabazitaxel was associated with nine additional modeled survivors, despite no significant OS difference (16.4 vs. 19.4 months).
Lu-PSMA showed improved PFS outcomes with eight additional patients progression-free and 15 more radiographic progression-free.
Cabazitaxel costs $107,729 per patient compared to $303,338 for Lu-PSMA, resulting in a cost difference of -$195,608.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Compares cabazitaxel and Lu-PSMA outcomes in mCRPC, suggesting cost advantages for cabazitaxel.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nault et al. (2026) studied this question.

synapsesocial.com/papers/6a782d4e2e1896536c8404b6 https://doi.org/10.1080/13696998.2026.2709297

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical and cost impact of cabazitaxel versus lutetium-177 vipivotide tetraxetan (Lu-PSMA) for patients with metastatic castration-resistant prostate cancer (mCRPC).Human Clinical Trial · 2026 · 1 citations
2Cost-Effectiveness Analysis of <sup>177</sup> Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care PerspectiveRetrospective Study · 2026 · 5 citations
3Outcomes of cabazitaxel following 177Lu-PSMA-617 (LuPSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC).Early-Phase Clinical Trial · 2026
4PSA response and cabazitaxel outcomes stratified by prior docetaxel PSA response in metastatic castrate-resistant prostate cancer (mCRPC).2024
5Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness AnalysesOriginal Research · 2026